Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

612 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
Mikulska M, Testi D, Russo C, Balletto E, Sepulcri C, Bussini L, Dentone C, Magne F, Policarpo S, Campoli C, Miselli F, Cilli A, Ghiggi C, Aquino S, Di Grazia C, Giannella M, Giacobbe DR, Vena A, Raiola AM, Bonifazi F, Zinzani P, Cavo M, Lemoli R, Angelucci E, Viale P, Bassetti M, Bartoletti M. Mikulska M, et al. Among authors: cavo m. Br J Haematol. 2023 May;201(4):628-639. doi: 10.1111/bjh.18690. Epub 2023 Feb 20. Br J Haematol. 2023. PMID: 36806152
A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G, Dicataldo M, Barone M, Storci G, De Matteis S, Laprovitera N, Sinigaglia B, Barbato F, Maffini E, Cavo M, Bonifazi F, Arpinati M. Chirumbolo G, et al. Among authors: cavo m. Transplant Cell Ther. 2023 May;29(5):302.e1-302.e8. doi: 10.1016/j.jtct.2023.02.008. Epub 2023 Feb 14. Transplant Cell Ther. 2023. PMID: 36796518 Free article.
Impact of a newly established expert clinical pharmacological advice programme based on therapeutic drug monitoring results in tailoring antimicrobial therapy hospital-wide in a tertiary university hospital: Findings after the first year of implementation.
Cojutti PG, Gatti M, Bonifazi F, Caramelli F, Castelli A, Cavo M, Cescon M, Corvaglia LT, Lanari M, Marinelli S, Morelli MC, Pession A, Poggioli G, Ramirez S, Siniscalchi A, Tonetti T, Trevisani F, Zanoni A, Zinzani PL, Gibertoni C, Viale P, Pea F. Cojutti PG, et al. Among authors: cavo m. Int J Antimicrob Agents. 2023 Aug;62(2):106884. doi: 10.1016/j.ijantimicag.2023.106884. Epub 2023 Jun 10. Int J Antimicrob Agents. 2023. PMID: 37302773 Free article.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isidori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, Bonifacio M, Palumbo GA. Palandri F, et al. Among authors: cavo m. Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18. Cancer. 2023. PMID: 36932983 Free article.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Among authors: cavo m. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.
Marconi G, Candoni A, Di Nicola R, Sartor C, Parisi S, Abbenante M, Nanni J, Cristiano G, Zannoni L, Lazzarotto D, Giannini B, Baldazzi C, Bandini L, Ottaviani E, Testoni N, Bezzi CDG, Abd-Alatif R, Ciotti G, Fanin R, Martinelli G, Paolini S, Ricci P, Cavo M, Papayannidis C, Curti A. Marconi G, et al. Among authors: cavo m. Cancer Med. 2023 May;12(10):11838-11848. doi: 10.1002/cam4.5858. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999931 Free PMC article.
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.
Mongiorgi S, De Stefano A, Ratti S, Indio V, Astolfi A, Casalin I, Pellagatti A, Paolini S, Parisi S, Cavo M, Pession A, McCubrey JA, Suh PG, Manzoli L, Boultwood J, Finelli C, Cocco L, Follo MY. Mongiorgi S, et al. Among authors: cavo m. Clin Epigenetics. 2023 Feb 20;15(1):27. doi: 10.1186/s13148-023-01441-9. Clin Epigenetics. 2023. PMID: 36803590 Free PMC article.
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability.
Forte D, Pellegrino RM, Trabanelli S, Tonetti T, Ricci F, Cenerenti M, Comai G, Tazzari P, Lazzarotto T, Buratta S, Urbanelli L, Narimanfar G, Alabed HBR, Mecucci C, La Manna G, Emiliani C, Jandus C, Ranieri VM, Cavo M, Catani L, Palandri F. Forte D, et al. Among authors: cavo m. Front Immunol. 2023 May 3;14:1085610. doi: 10.3389/fimmu.2023.1085610. eCollection 2023. Front Immunol. 2023. PMID: 37207201 Free PMC article.
612 results